Miller Megan, Meyers Molly, Martin Annona, Napolitano Stephanie, Dorsen Caroline, Penn Andrew, Rosa William E
J Hosp Palliat Nurs. 2025 Apr 1;27(2):67-73. doi: 10.1097/NJH.0000000000001096. Epub 2024 Dec 19.
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence suggests possible utility of PAT for addressing psychosocial-spiritual-existential concerns, yet gaps remain in understanding findings related to PAT's role in palliative care. This rapid review aims to synthesize current literature on applications of PAT in the context of palliative care. Through a systematic process, we identified 34 articles published between January 2021 and July 2024. Protocols varied yet included common components of participant screening, preparation, dosing, and integration. Psilocybin was the most commonly studied compound. Results support safety and initial efficacy of PAT for psycho-spiritual-existential outcomes among carefully screened and highly homogonous samples of patients with serious illness (predominantly cancer). Current efforts and challenges around integrating PAT into systems of palliative care were highlighted. Additional work is needed to (1) explore PAT's safety and efficacy within more diverse samples and contexts, (2) train palliative care providers on PAT, (3) determine systems of care delivery best suited for translation of PAT into practice, and (4) begin developing policy solutions to support safe and equitable access to PAT. Because many patients lack access to basic psychosocial-spiritual-existential care, careful consideration is needed around integration of PAT. The psychedelic substances which are the topic of this article are not currently FDA approved for use in the United States.
迷幻辅助疗法(PAT)是指在精心策划的环境中,在迷幻药物的辅助下进行体验。早期证据表明,PAT在解决心理社会-精神-存在性问题方面可能具有效用,但在理解PAT在姑息治疗中的作用相关研究结果方面仍存在差距。本快速综述旨在综合当前关于PAT在姑息治疗背景下应用的文献。通过系统的过程,我们确定了2021年1月至2024年7月期间发表的34篇文章。方案各不相同,但包括参与者筛选、准备、给药和整合等共同组成部分。裸盖菇素是研究最广泛的化合物。结果支持了PAT在经过仔细筛选且高度同质的重症患者(主要是癌症患者)样本中对心理-精神-存在性结果的安全性和初步疗效。文中强调了目前将PAT纳入姑息治疗体系的努力和挑战。还需要开展更多工作,以(1)在更多样化的样本和背景下探索PAT的安全性和疗效,(2)对姑息治疗提供者进行PAT培训,(3)确定最适合将PAT转化为实践的护理提供系统,以及(4)开始制定政策解决方案,以支持安全、公平地获得PAT。由于许多患者无法获得基本的心理社会-精神-存在性护理,因此在将PAT纳入时需要仔细考虑。本文所讨论的迷幻物质目前尚未获得美国食品药品监督管理局(FDA)的批准在美国使用。